During the first nine months of fiscal 2009, the Company repurchased 5,315 shares of our common stock under a previously announced buyback plan for approximately $106,000. In addition, the Company has a remaining commitment of approximately $236,000 for automation of certain manufacturing processes for its Raven line of biological indicators. This equipment began limited production during December and final payment against this commitment is expected during the fourth quarter.
Mesa Laboratories develops, acquires, manufactures and markets electronic instruments and disposables for industrial, pharmaceutical and medical applications.
This news release contains forward-looking statements which involve risks and uncertainties. The Company's actual results could differ materially from those in any such forward-looking statements. Additional information concerning important factors that could cause results to differ materially from those in any such forward-looking statement is contained in the Company's Annual Report on Form-10K for the year ended March 31, 2008 as filed with the Securities and Exchange Commission, and from time to time in the Company's other reports on file with the Commission.
FINANCIAL SUMMARY STATEMENT OF EARNINGS (Unaudited) Quarter Ended Nine Months Ended December 31 December 31 2008 2007 2008 2007 Net Sales $5,337,000 $4,614,000 $16,071,000 $13,768,000 Cost of Goods 1,903,000 1,527,000 5,786,000 4,494,000 Gross Profit 3,434,000 3,087,000 10,285,000 9,274,000 Opera
|SOURCE Mesa Laboratories, Inc.|
Copyright©2009 PR Newswire.
All rights reserved